|
Astrie Therapeutics, Inc. (ATXS) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Astria Therapeutics, Inc. (ATXS) Bundle
Mit unserem ATXS DCF-Taschenrechner, der für die Genauigkeit entwickelt wurde, können Sie die Bewertung von Astrie Therapeutics, Inc. unter Verwendung realer Finanzdaten bewerten und gleichzeitig vollständige Flexibilität bieten, um alle wesentlichen Parameter für verbesserte Projektionen zu ändern.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -26.3 | -37.4 | -195.0 | -53.5 | -83.0 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .0 | .0 | -164.6 | .2 | -15.2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -26.3 | -37.5 | -30.4 | -53.7 | -67.8 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 36.2 | 44.9 | 125.5 | 226.4 | 246.5 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 1.2 | 1.5 | 1.6 | .8 | 1.5 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | -.1 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -26.2 | -37.2 | -4.7 | -52.0 | -67.8 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -25.0 | -36.9 | -169.3 | -52.6 | -82.3 | -1.5 | .0 | .0 | .0 | .0 |
| WACC, % | 7.21 | 7.21 | 7.2 | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -1 | |||||||||
| Net Debt | -175 | |||||||||
| Equity Value | 174 | |||||||||
| Diluted Shares Outstanding, MM | 30 | |||||||||
| Equity Value Per Share | 5.77 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real ATXS financials.
- Real-World Data: Historical data and forward-looking estimates (highlighted in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe how your inputs affect Astria Therapeutics' valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and simplicity, complete with step-by-step instructions.
Key Features
- Customizable Clinical Parameters: Adjust essential inputs like patient enrollment rates, treatment efficacy, and cost of goods sold.
- Instant Valuation Metrics: Quickly calculates intrinsic value, NPV, and other key financial indicators.
- High-Precision Analytics: Leverages Astria Therapeutics' real-world data for accurate valuation results.
- Streamlined Scenario Testing: Easily evaluate various hypotheses and analyze their impacts.
- Efficiency Booster: Avoid the hassle of creating intricate valuation models from the ground up.
How It Works
- Download the Template: Gain immediate access to the Excel-based ATXS DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional variables.
- Instant Calculations: The model will automatically refresh to display Astria Therapeutics’ intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the findings to inform your investment or financial strategy.
Why Choose Astria Therapeutics' Calculator?
- Comprehensive Tool: Offers DCF, WACC, and financial ratio analyses all in one convenient package.
- Customizable Inputs: Modify yellow-highlighted cells to explore different scenarios.
- Detailed Insights: Automatically computes the intrinsic value and Net Present Value for Astria Therapeutics (ATXS).
- Preloaded Data: Includes historical and forecasted data to provide accurate starting points.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focused on the biotech sector.
Who Should Use This Product?
- Investors: Evaluate Astria Therapeutics, Inc.'s (ATXS) market potential before making investment decisions.
- CFOs and Financial Analysts: Enhance valuation methodologies and validate financial forecasts for ATXS.
- Startup Founders: Discover the valuation strategies of established biotech firms like Astria Therapeutics.
- Consultants: Provide comprehensive valuation analyses and reports for clients interested in biotech investments.
- Students and Educators: Utilize current data to learn and teach valuation methods in the context of the biotech industry.
What the Template Contains
- Pre-Filled DCF Model: Astria Therapeutics’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Astria Therapeutics’ profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.